382 related articles for article (PubMed ID: 8388825)
1. Ethical and safety considerations for the use in clinical trials of new attenuated poliovirus strains.
Horaud F
Dev Biol Stand; 1993; 78():149-54; discussion 154-5. PubMed ID: 8388825
[No Abstract] [Full Text] [Related]
2. The potential use of viral genomic markers in estimating the neurovirulence of oral poliomyelitis vaccine (OPV): regulatory aspects.
Fenyves A
Dev Biol Stand; 1993; 78():157-9. PubMed ID: 8388826
[No Abstract] [Full Text] [Related]
3. Virology. Poliomyelitis eradication--a dangerous endgame.
Nathanson N; Fine P
Science; 2002 Apr; 296(5566):269-70. PubMed ID: 11951020
[No Abstract] [Full Text] [Related]
4. Changing poliovirus vaccine policy can be controversial at best.
Faden H
Adv Pediatr Infect Dis; 1997; 13():305-32. PubMed ID: 9544317
[No Abstract] [Full Text] [Related]
5. Studies on new attenuated strains of type III live poliomyelitis vaccine. II. Field trials of Zhong III2 virus.
Chin Med J (Engl); 1980 Sep; 93(9):591-8. PubMed ID: 6253237
[No Abstract] [Full Text] [Related]
6. WHO recommendation on potential use of new poliomyelitis vaccines.
Ghendon Y
Dev Biol Stand; 1993; 78():133-7; discussion 138-9. PubMed ID: 8388823
[TBL] [Abstract][Full Text] [Related]
7. [Poliomyelitis vaccine].
Horie H
Nihon Rinsho; 2005 May; 63 Suppl 5():601-6. PubMed ID: 15954416
[No Abstract] [Full Text] [Related]
8. Attenuation and reversion of the Sabin vaccine strains of poliovirus.
Minor PD
Dev Biol Stand; 1993; 78():17-26. PubMed ID: 8388828
[TBL] [Abstract][Full Text] [Related]
9. Infectious diseases. Polio outbreak raises questions about vaccine.
Greensfelder L
Science; 2000 Dec; 290(5498):1867-9. PubMed ID: 11187033
[No Abstract] [Full Text] [Related]
10. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
11. Infectious disease. Vaccine-related polio outbreak in Nigeria raises concerns.
Roberts L
Science; 2007 Sep; 317(5846):1842. PubMed ID: 17901301
[No Abstract] [Full Text] [Related]
12. Reflections on the qualitative and quantitative aspects of neurovirulence of different polioviruses.
Sabin AB
Dev Biol Stand; 1993; 78():3-7. PubMed ID: 8388830
[No Abstract] [Full Text] [Related]
13. An historical outline of the development of live poliovaccine and its non-target effects.
Horaud F
Dev Biol Stand; 1995; 84():117-22. PubMed ID: 7796943
[No Abstract] [Full Text] [Related]
14. Circulating vaccine-derived polioviruses: current state of knowledge.
Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
[TBL] [Abstract][Full Text] [Related]
15. Polio vaccine: should New Zealand make the change?
Baker C; Eberhart-Phillips J
N Z Med J; 1997 Sep; 110(1051):340-2. PubMed ID: 9323376
[No Abstract] [Full Text] [Related]
16. Scientific specialization and the poliovirus controversy in the years before World War II.
Grimshaw ML
Bull Hist Med; 1995; 69(1):44-65. PubMed ID: 7711459
[No Abstract] [Full Text] [Related]
17. [End phase challenges of poliomyelitis eradication programme realization].
Jarzabek Z
Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
[TBL] [Abstract][Full Text] [Related]
18. [On an epidemic outbreak of poliomyelitis, type 3, in the Voivode County of Poznań in 1968].
Walter T
Zentralbl Bakteriol Orig; 1969; 211(2):162-6. PubMed ID: 4318358
[No Abstract] [Full Text] [Related]
19. [Medical management of poliomyelitis cases during the Warsaw outbreak in 1950's].
Czachorowska M
Przegl Epidemiol; 2002; 56(4):541-6. PubMed ID: 12666579
[TBL] [Abstract][Full Text] [Related]
20. Significance of a newly identified attenuating mutation in Sabin 3 oral poliovirus vaccine.
Mento SJ; Weeks-Levy C; Tatem JM; Gorgacz EJ; Waterfield WF
Dev Biol Stand; 1993; 78():93-9; discussion 99-100. PubMed ID: 8388835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
